AlloVir, Inc. (ALVR)
| Market Cap | 47.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -100.20M |
| Shares Out | 4.98M |
| EPS (ttm) | -20.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,065 |
| Open | 9.97 |
| Previous Close | 9.67 |
| Day's Range | 9.62 - 9.97 |
| 52-Week Range | 7.96 - 24.15 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 14, 2025 |
About ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenz... [Read more]
Financial Performance
Financial StatementsNews
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders
NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients wit...
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ: ALVR) breached their ...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the...
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the...
MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the...
INVESTOR DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the ...
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR
NEW YORK , March 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AlloVir, Inc.. Shareholders who purchased shares of ALVR during the class period listed are e...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the ...
MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the ...
IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the ...
IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the ...
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Jo...
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "t...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "t...
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
AlloVir shedding 95% of its staff after discontinuing T cell therapy trial
AlloVir Inc. ALVR, +5.02%, a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff, following an announcement las...
AlloVir's stock suffers record plunge toward a record low after trials on T cell therapy
Shares of AlloVir Inc. ALVR, -66.75% plummeted 66.6% toward their first-ever close below $1 on heavy volume in afternoon trading Friday, after the immunotherapy company decided to discontinue the Phas...
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety conce...
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p...
AlloVir Reports Third Quarter 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30...
AlloVir to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p...
AlloVir Reports Second Quarter 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the second quarter ended June 30, 20...